… using anticoagulation with Vitamin-K antagonists (VKA) were … a comparable bleeding risk
for apixaban and ASA [19, 20]. In … comparing non-vitamin K oral anticoagulants to Vitamin K-…

… and Drug Administration (FDA) for stroke prevention in non-valvular atrial fibrillation (NVAF), …
to vitamin K antagonists (VKAs), and can be prescribed in fixed doses without routine …

… of apixaban. The review found that switching among OACs was common in clinical practice,
… The benefits of oral anticoagulants (OACs), both vitamin K antagonists (VKAs) and direct-…

… Despite this recommendation, data regarding contemporary routine clinical practice reveal a
… anticoagulants in patients with atrial fibrillation: a real-world analysis of German claims data …

… anticoagulants globally, overtaking vitamin K antagonists (VKAs)… , apixaban, edoxaban)
and do not require routine laboratory … on AF patients from a large German health insurance …

… frequent event in daily clinical practice, 5–11 estimated … non-vitamin K antagonist oral
anticoagulants in patients with … ) for rivaroxaban, 2.5 mg bid for apixaban and 30 mg QD for …

… vitamin K antagonists (VKAs) and apixaban among patients … apixaban, LMWH, or warfarin
in routine clinical practice. … if they had any evidence of atrial fibrillation/flutter or a mechanical …

… Before 2010, the numerous limitations associated with vitamin K antagonists (VKAs) were …
particularly apixaban) when a bleeding risk is anticipated or observed is a growing practice by …

… seen in a clinical trial population will be realized in actual clinical practice. Specific to DOAC
… , comparative efficacy studies between the most commonly used DOACs, apixaban and …

… Non-vitamin K antagonist oral anticoagulants represent a … of 231 833 AF patients from 1857
general practices in UK … between CCI score and the relative efficacy, safety, or net outcomes …